Medications based on personal need as determined by third-party clinician
Packaging that leads with protein content (20g Protein Per Serving), uses protein-signaling ingredient language (quinoa, lentils, pea protein), and presents clean, minimal ingredient lists will consistently outperform traditional packaging with GLP-1 consumers
However, a review of recent studies indicates that this is soon to change as more clinicians become aware of the unique advantages of nasal delivery of peptides and other therapeutics
Yang, J., Wang, Z
A 2026 study published in Cardiovascular Diabetology found an association between GLP-1 use and lower risks of heart attack, stroke, heart failure and premature death among high-risk patients building on earlier evidence from Novo Nordisk's SELECT trial, which showed that Wegovy reduced major adverse cardiovascular events versus placebo in people with established heart disease
Terrier P, Townsend AJ, Coindre JM, Triche TJ, Cowan KH (October 1990)